• Home
  • Biopharmaceutical Research Services
  • Multi-Omics Services
  • Support
  • /assets/images/icon/icon-email-2.png

    Email:

    info@MtoZ-Biolabs.com

    Neoantigen Identification

      Neoantigen identification involves identifying and validating novel antigen molecules produced by specific tumors using bioinformatics tools and experimental methods. These neoantigens are derived from tumor-specific mutations that differ significantly from normal cell antigens, enabling them to be recognized by the immune system and initiate immune responses. Neoantigens arise due to genetic mutations accumulated during the proliferation and division of cancer cells, resulting in the production of abnormal protein fragments. Their high degree of individual specificity makes neoantigens ideal targets for personalized cancer immunotherapy.

       

      Neoantigen identification has extensive applications, particularly in cancer immunotherapy. Since neoantigens are typically expressed exclusively in tumor cells, they serve as highly specific targets for immune system recognition and elimination. This unique characteristic underpins the development of personalized cancer vaccines and T-cell-based therapies. By identifying patient-specific neoantigens, researchers can design tailored vaccines to activate the patient’s immune system against cancer cells. Additionally, neoantigen identification contributes to understanding the tumor immune microenvironment by uncovering mechanisms of immune evasion, offering valuable insights for developing novel treatment strategies.

       

      Accurate identification of neoantigens not only enhances therapeutic precision and efficacy but also minimizes the side effects associated with conventional therapies. Neoantigen identification technologies can pinpoint immunogenic mutations-those capable of eliciting immune responses-which are potential therapeutic targets. This process comprises several steps, including bioinformatics analysis, mass spectrometry-based validation, and immunological evaluation. This comprehensive strategy ensures that the identified neoantigens exhibit strong immunogenicity and tumor specificity.

       

      The workflow for neoantigen identification begins with whole-exome or whole-genome sequencing of tumor samples to identify genetic mutations. Bioinformatics tools are then used to predict mutations likely to generate immunogenic neoantigens. Next, mass spectrometry and in vitro immunological assays validate the expression and immunogenicity of these neoantigens. These rigorous steps establish the accuracy and clinical relevance of neoantigen targets, forming the foundation for personalized immunotherapy.

       

      MtoZ Biolabs provides comprehensive and high-quality services in neoantigen identification for researchers and clinicians. We welcome opportunities to collaborate with new partners. Please feel free to contact us for more information.

       

      MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.

    Submit Inquiry
    Name *
    Email Address *
    Phone Number
    Inquiry Project
    Project Description *

     

    How to order?


    /assets/images/icon/icon-message.png

    Submit Inquiry

    /assets/images/icon/icon-return.png